Lamotrigine is not approved to treat ADHD, and no major clinical guideline recommends it for that purpose. The small body of research that does exist, however, paints an interesting picture: in certain subgroups, particularly people who have both ADHD and epilepsy or both ADHD and a mood disorder, lamotrigine appears to reduce ADHD symptoms to a degree that some researchers consider clinically meaningful. The catch is that the evidence comes from a handful of small studies, and the question of whether lamotrigine helps “pure” ADHD without a co-occurring condition remains essentially unanswered.
What the Available Studies Show
The most commonly cited study on this topic looked at 90 children with epilepsy who were started on lamotrigine as their seizure medication. Researchers measured their ADHD symptoms before and after treatment. When you look at all 90 kids together, the improvement in attention and hyperactivity scores was slight and not statistically meaningful. But a subset of those children, about a third, actually met diagnostic criteria for ADHD before starting lamotrigine. In that group, the results were strikingly different: roughly 87% showed lower ADHD scores after treatment, and the average total ADHD score dropped from about 28 to about 18, a reduction that was both statistically and clinically significant. Scores for both inattention and hyperactivity-impulsivity improved substantially in this subgroup.1PubMed Central. Effects of lamotrigine on attention-deficit hyperactivity disorder in pediatric epilepsy patients
The other key piece of evidence comes from a case series of 40 adults with ADHD who also had either bipolar II disorder or recurrent depression. These patients were treated with lamotrigine at doses averaging around 125 mg per day. About three-quarters of them improved on clinical rating scales, while roughly one in six showed no change and two patients actually got worse.2PubMed. Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series The researchers described it as the first study to suggest lamotrigine could be a safe and effective option for adults with ADHD when it coexists with mood problems.
Both studies are worth knowing about, but both have real limitations. Neither was a randomized controlled trial. Neither had a placebo comparison group. And both involved patients who had conditions beyond ADHD that lamotrigine is already known to treat. That makes it hard to tease apart whether the drug improved ADHD symptoms directly or whether controlling seizures or stabilizing mood had knock-on benefits for attention and behavior.
Why Lamotrigine Is Not a Standard ADHD Medication
Standard first-line ADHD treatments, stimulant medications and certain non-stimulant options, have decades of large-scale evidence supporting them. They work by boosting dopamine and norepinephrine activity in areas of the brain responsible for attention, impulse control, and executive function. Lamotrigine works through a fundamentally different pathway. It primarily blocks voltage-gated sodium channels in the brain, which reduces the firing of overactive neurons. It also modulates glutamate, an excitatory brain chemical. These mechanisms make it effective for seizure prevention and mood stabilization but don’t target the dopamine and norepinephrine systems that are central to ADHD.
A review of the evidence on lamotrigine’s various psychiatric uses concluded that the level of support for off-label prescribing varies enormously depending on the condition, and that clinicians need to exercise careful judgment about where it actually fits in treatment.3American Journal of Therapeutics. Lamotrigine Uses in Psychiatric Practice For ADHD specifically, the evidence sits near the bottom of that hierarchy. There are no phase III clinical trials, no head-to-head comparisons with established ADHD medications, and no dose-finding studies designed specifically for ADHD symptoms.
When researchers have looked broadly at combining multiple medications for psychiatric conditions in children and adolescents, only one combination strategy for ADHD has been backed by substantial evidence with a large enough effect to matter clinically: adding a certain class of blood-pressure-lowering medications to stimulants.4SpringerLink / Paediatr Drugs. Combination pharmacotherapy for psychiatric disorders in children and adolescents: prevalence, efficacy, risks and research needs Lamotrigine doesn’t appear in that short list of well-supported add-on strategies.
The Epilepsy-ADHD Connection
ADHD occurs more often in people with epilepsy than in the general population, and the two conditions share some overlapping brain-circuit disruptions. Children with epilepsy face a particular bind: some seizure medications can worsen attention problems or make kids feel mentally foggy, creating a situation where treating one condition aggravates the other. This is one reason lamotrigine generates interest. Among the commonly used anti-seizure medications, it has a reputation for being relatively “brain-friendly.”
A review of the challenges of treating epilepsy-ADHD comorbidity specifically noted that lamotrigine, along with carbamazepine, exerts favorable effects on attention and behavior.5PubMed. The Challenge of Pharmacotherapy in Children and Adolescents with Epilepsy-ADHD Comorbidity This doesn’t mean lamotrigine is prescribed to treat ADHD in these patients. Rather, when a child with both conditions needs an anti-seizure drug, choosing one that doesn’t harm attention and may even help it is a meaningful clinical advantage. For a neurologist selecting among several effective seizure medications, the cognitive profile of each drug can tip the decision.
Lamotrigine’s Cognitive Profile Compared to Other Anticonvulsants
One of the practical reasons lamotrigine keeps showing up in discussions about attention is that it compares favorably to other seizure medications when it comes to thinking clearly. A study that tracked patients over the longer term on three different anti-seizure drugs found that topiramate caused significant deterioration in executive function, which includes skills like planning, mental flexibility, and working memory. More than half the patients on topiramate lost ground in this area, and none improved. By comparison, patients on lamotrigine had a much more balanced profile: about a quarter showed some decline in executive function, but about a quarter actually improved. On subjective reports, no lamotrigine patients complained of increased cognitive problems, while more than half the topiramate patients did.6PubMed. The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting
This matters for the ADHD conversation not because it proves lamotrigine treats ADHD but because it shows the drug generally doesn’t impair the very cognitive functions that ADHD already disrupts. If you’re someone with both epilepsy and attention problems, a medication that controls seizures without worsening your ability to concentrate is doing double duty even if it isn’t specifically targeting ADHD.
Emotional Dysregulation and Where Mood Stabilizers May Fit
ADHD is commonly thought of as a disorder of attention and hyperactivity, but emotional dysregulation is increasingly recognized as a core feature. Many people with ADHD experience intense emotional reactions, rapid mood shifts, and difficulty regulating frustration and anger. These symptoms overlap considerably with what mood stabilizers like lamotrigine are designed to address, which is part of why the two worlds keep bumping into each other.
Research on mood stabilizers used alongside standard ADHD medications in adults found that adding a mood stabilizer to methylphenidate significantly reduced emotional dysregulation, including negative emotionality and emotional impulsivity. Those treated with a mood stabilizer alongside their stimulant also saw improvement in affective instability, something that didn’t improve in the group taking a non-stimulant ADHD drug without a mood stabilizer.7PubMed Central. Mood Stabilizers for Treating Emotional Dysregulation in Adults with Attention-Deficit/Hyperactivity Disorder with or Without Comorbid Bipolar Spectrum Disorders This research encompassed mood stabilizers as a class rather than singling out lamotrigine specifically, but it helps explain the rationale: for people whose ADHD symptoms are heavily emotional rather than purely attentional, a mood stabilizer might address a dimension that stimulants alone leave partially untreated.
The Bipolar-ADHD Diagnostic Tangle
One scenario where lamotrigine becomes genuinely important in ADHD-related care involves the tricky diagnostic overlap between ADHD and bipolar disorder. The two conditions share symptoms like impulsivity, restlessness, difficulty concentrating, and poor sleep. Misdiagnosing bipolar disorder as pure ADHD can have serious consequences because stimulant medications, the standard ADHD treatment, can trigger manic or hypomanic episodes in people with unrecognized bipolar disorder.
A case report illustrates this risk clearly. A 34-year-old man was started on methylphenidate for what was presumed to be adult ADHD. He soon developed symptoms of hypomania, including elevated mood, reduced need for sleep, and impulsive behavior. A closer psychiatric evaluation revealed an undiagnosed history consistent with bipolar II disorder. Methylphenidate was stopped, and his mood was stabilized with lamotrigine.8Archives of Medical Reports. Methylphenidate-Induced Hypomania in an Adult with Undiagnosed Bipolar II Disorder and ADHD: A Case Report
This is the type of situation where lamotrigine fills a genuine gap. Once a mood disorder is identified, treating it first or alongside the ADHD becomes the priority, because stabilizing mood can itself reduce some of the concentration and impulsivity problems. For a patient who cannot tolerate stimulants because of bipolar risk, having a mood stabilizer that also appears to improve attention-related symptoms, even modestly, is valuable. The case series of 40 adults with both ADHD and mood disorders found that about three-quarters improved with lamotrigine alone, suggesting that for some patients, stabilizing the mood disorder may be sufficient to bring ADHD symptoms down to a manageable level.2PubMed. Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series
Safety and the Slow Titration Requirement
Anyone considering lamotrigine should be aware that it carries a specific and serious, though uncommon, safety concern: Stevens-Johnson syndrome (SJS), a severe skin reaction involving blistering and detachment of the skin surface. Among anti-seizure drugs, lamotrigine is one of the most commonly associated with this reaction.9PubMed Central. Lamotrigine and Stevens-Johnson Syndrome Prevention The risk is higher in certain genetic backgrounds. People of Southeast Asian descent, particularly those of Chinese heritage, may carry a genetic variant that increases susceptibility. Similar variants have been identified in people of Japanese and Korean ancestry. The FDA recommends genetic testing for these variants before starting the drug.
The primary way clinicians manage this risk is through a very slow dose increase. Lamotrigine is typically started at a low dose and raised gradually over several weeks. This slow ramp-up is unlike stimulant ADHD medications, which usually reach a therapeutic dose within days. For someone hoping for quick relief of attention problems, this weeks-long titration is a practical drawback. One study tracking patients through various initial titration schedules found that when the slow-start protocol was followed, no cases of severe rash occurred at all.10PubMed Central. Impact of Selected Initial Titration Schedules on Safety and Long-Term Effectiveness of Lamotrigine for the Treatment of Mood Disorders The takeaway is that the serious rash risk is manageable when dosing guidelines are respected, but it adds complexity and patience to the treatment process.
Beyond the rash risk, lamotrigine’s everyday side-effect profile is generally considered mild. Common complaints include headache, dizziness, and nausea, particularly during the dose-escalation phase. Compared to stimulant medications, lamotrigine does not suppress appetite or raise blood pressure. Compared to some other mood stabilizers, it doesn’t tend to cause weight gain or the metabolic problems associated with certain antipsychotics. These relative advantages explain why some psychiatrists gravitate toward it when managing complex cases that straddle the boundary between mood disorders and ADHD.
Who Might Actually Be Prescribed Lamotrigine for ADHD Symptoms
Given the state of the evidence, a few specific patient profiles are most likely to encounter lamotrigine as part of their ADHD-related care. The first is someone with epilepsy and co-occurring ADHD, where lamotrigine can serve as the seizure medication of choice partly because it doesn’t worsen attention. The second is someone diagnosed with both ADHD and bipolar disorder, particularly bipolar II, where lamotrigine is already an established maintenance treatment for mood episodes and may carry additional benefits for attention and impulsivity. The third is someone whose ADHD symptoms are dominated by emotional dysregulation rather than classic inattention, where the mood-stabilizing properties may address a dimension that stimulants miss.
None of these scenarios involve prescribing lamotrigine as a standalone ADHD treatment in someone without a comorbid condition. And the evidence base, as it stands, doesn’t justify that approach. If you have straightforward ADHD without epilepsy or a mood disorder, the research simply isn’t there to support lamotrigine as your primary medication. Established ADHD treatments have far stronger evidence, work faster, and have well-characterized dose-response relationships.
What to Ask Your Prescriber
If you have ADHD and are already taking lamotrigine for another reason, or if your clinician has suggested it, there are some practical questions worth raising. Ask whether the prescribing rationale is specifically for ADHD symptoms or for a co-occurring condition that might indirectly improve attention. Ask how improvement will be tracked, since there are no standardized protocols for monitoring lamotrigine’s effect on ADHD the way there are for stimulant dose optimization. And if you carry both an ADHD diagnosis and any suspicion of a mood disorder, ask whether formal mood assessment has been completed before stimulants are considered, given the risk of triggering mood episodes.
It’s also worth understanding that some people on lamotrigine for mood or seizure control notice subjective improvements in focus and mental clarity that aren’t being measured in a clinical study. These observations are real and valid, but they can reflect better sleep from mood stabilization, reduced anxiety, or simply the cognitive benefit of not having uncontrolled seizures or mood cycling. Teasing apart a direct attention-enhancing effect from the downstream benefits of treating the primary condition is genuinely difficult, and the existing research hasn’t been designed to do that cleanly.
Genetic Testing and Personalized Prescribing
The genetic dimension of lamotrigine prescribing is more advanced than for most psychiatric medications. Because certain HLA gene variants are associated with severe skin reactions, pre-treatment genetic screening is becoming more standard, especially in populations with higher carrier rates.9PubMed Central. Lamotrigine and Stevens-Johnson Syndrome Prevention This represents a rare example in psychiatry where pharmacogenomic testing directly influences whether a drug should be started at all, not just how effective it might be. For patients of East or Southeast Asian descent, this testing is particularly important and should be considered routine before the first dose.
Pharmacogenomic research is also beginning to look at whether certain genetic profiles predict who will respond well to lamotrigine for mood stabilization, though this work hasn’t yet extended to ADHD-specific outcomes. As the field develops, it’s possible that genetic markers could eventually help identify the subset of ADHD patients most likely to benefit from lamotrigine, moving the conversation beyond the broad-strokes evidence that exists today. For now, though, clinical decision-making relies on the patient’s full diagnostic picture and treatment history rather than any genetic test for ADHD response.